Biotickr logobiotickr

Company Description

HCW Biologics is a clinical-stage company advancing development of transformative immunotherapies to lengthen healthspan by disrupting inflammaging.

HCW Biologics is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease.


HCW Biologics has combined a deep understanding of disease-related immunology with expertise in advanced protein engineering to develop TOBI™ (Tissue factOr-Based fusIon), a proprietary immunotherapeutic drug design and discovery platform¹.

By harnessing this modular and tunable technology, we have generated a novel pipeline of product candidates that we believe are capable of activating and targeting desired immune responses while also blocking unwanted immunosuppressive activities¹.

Built around a Tissue Factor (TF) scaffold, the TOBI platform has the potential to pack multiple protein targets, including cytokines, single-chain antibodies, and ligands, into a fusion molecule capable of engaging immunostimulatory functions and addressing many signaling pathways simultaneously. Some of these fusion protein complexes have ex vivo and in vivo applications for stimulating natural killer (NK) and T cells for cancer-cell and senescent-cell killing and blocking immunosuppression. Moreover, the TOBI platform is reproducible and suitable for cGMP manufacturing.

Drug Pipeline

Source: HCW Biologics Inc - 20221117
Acute Myeloid Leukemia
Phase 2
Liver Cancer
Non-Alcoholic Fatty Liver Disease
Pancreatic Cancer
Phase 1
Solid Tumors
Phase 1
Alopecia Areata
Autoimmune Disease


0 following
Messages Image
Log in or sign up to join the conversation.

0 Comments on HCWB stock